This document summarizes a workshop discussing sustainable funding and fair pricing for orphan drugs in Europe. It presented data on the variation in funding and approval of orphan drugs across EU countries. While Germany and France most widely provide access, only 30-60% of orphan drugs are reimbursed in other countries like England, Italy, Scotland, and Wales. The shortest time from approval to reimbursement decision is 19 months in France and Italy, while it is 28.5 months in England and Wales. The workshop aimed to discuss options for making orphan drug funding sustainable for healthcare systems while providing fair rewards to their manufacturers.